Author

B. Serrels

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Biochemistry· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 6 Approach:experimental assay· 5 Assay:proteomics· 4 Research Focus:cell type annotation· 3 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:protein folding & dynamics· 2

Frequent Co-Authors

A. Byron· 4 shared N. O. Carragher· 4 shared J. C. Dawson· 3 shared A. Cartier· 2 shared A. von Kriegsheim· 2 shared B. Ouine· 2 shared K. G. Macleod· 2 shared L. de Koning· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Byron

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma

C. A. Ford, D. Koludrovic, P. P. Centeno, M. Foth, E. Tsonou, N. Vlahov, N. Sphyris, K. Gilroy, C. Bull, C. Nixon, B. Serrels, A. F. Munro, J. C. Dawson, N. O. Carragher, V. Pavet, , A. D. Campbell

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

bioRxiv · Feb 26, 2024Cancer Biology

Multicenter reverse-phase protein array data integration

L. de Koning, S. Bernhardt, K. G. Macleod, B. Ouine, A. Cartier, V. Sibut, N. O. Carragher, U. Korf, B. Serrels, A. Byron

This paper integrates multicenter reverse-phase protein array data from breast cancer cell responses to two drugs, quantifying 86,832 spots across three platforms to create a public resource for comparing RPPA workflows.

bioRxiv · Aug 31, 2021 · PreprintBiochemistry

Characterisation of a nucleo-adhesome

A. Byron, B. G. C. Griffith, A. Herrero, A. E. P. Loftus, E. S. Koeleman, J. C. Dawson, L. Kogerman, N. McGivern, J. Culley, G. R. Grimes, B. Serrels, A. von Kriegsheim, V. G. Brunton, M. C. Frame

The paper identifies a nucleo-adhesome, showing that adhesion proteins localize to the nucleus and regulate transcription through interactions like FAK and Hic-5.

bioRxiv · Aug 31, 2021Cell Biology

Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies

A. Byron, S. Bernhardt, B. Ouine, A. Cartier, K. G. Macleod, N. O. Carragher, V. Sibut, U. Korf, B. Serrels, L. de Koning

The paper assesses variability between RPPA platforms and identifies consistent protein expression and phosphorylation signatures across different platforms and workflows.

bioRxiv · Sep 16, 2019Cancer Biology

Targeting DNA damage response and Replication Stress in Pancreatic Cancer

S. Dreyer, R. Upstill-Goddard, V. Paulus-Hock, C. Paris, E. Maria-Lampraki, E. Dray, B. Serrels, S. Rebus, H. Brunton, C. Nourse, U.-M. Bailey, M. Jones, K. Moran-Jones, D. Wright, F. Duthie, , Lord

The paper identifies novel therapeutic strategies for pancreatic cancer by analyzing DNA damage response and replication stress in patient-derived cell lines.

bioRxiv · Jul 24, 2019Cancer Biology

A Synergistic Anti-Cancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High Content Phenotypic Screen

J. C. Dawson, B. Serrels, A. Byron, M. Muir, A. Makda, A. Garcia-Munoz, A. von Kriegsheim, N. O. Carragher, M. C. Frame

The paper identifies a synergistic combination of FAK and HDAC inhibitors using a chemical-genetic high-content screen, showing efficacy in cancer cell lines and in vivo.

bioRxiv · Mar 27, 2019Cancer Biology